Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer

Jingwei Xie, Chenlu Lei, Yong Hu, Gary Kaizhong Gay, Nazrul Hadi Bin Jamali, Chi Hwa Wang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Paclitaxel appears to be a potential substrate of the multidrug resistance protein p-glycoprotein, thus preventing itself from entry into the brain and penetrating blood-brain barrier poorly. In this study, the main objective was to design paclitaxel formulation using PLGA-based nanoparticles with different additives and surface coatings to facilitate the paclitaxel transport through MDCK cell monolayer. PLGA-based nanoparticles of around 200 nm without and with additives and surface coatings were developed by direct dialysis. The transendothelial electrical resistance (TEER) variation of MDCK cell monolayer on the cell inserts imposed by paclitaxel-loaded nanoparticles with and without additives was investigated. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) (MTT) assay was used to quantify the cell viability of C6 glioma cells after administration of formulations on the topical side. Investigations showed that particles with additives were able to enhance cellular uptake more than surface-coated particles. TEER values dropped upon the introduction of paclitaxel-loaded PLGA nanoparticles to the cell inserts. After incubation for 24 h, the cell viability of C6 glioma cells in the wells treated with nanoparticles was lower than that of the control wells without particles. Taken together, PLGA nanoparticles with vitamin E TPGS and polysorbate 80 as additives were successfully obtained as paclitaxel formulations, demonstrating great potential for the delivery of paclitaxel through MDCK cell monolayer in vitro.

Original languageEnglish (US)
Pages (from-to)2331-2340
Number of pages10
JournalCurrent Pharmaceutical Design
Volume16
Issue number21
DOIs
StatePublished - Aug 20 2010

Fingerprint

Madin Darby Canine Kidney Cells
Paclitaxel
Nanoparticles
Electric Impedance
Glioma
Cell Survival
P-Glycoproteins
Polysorbates
Blood-Brain Barrier
Dialysis
Glycoproteins
polylactic acid-polyglycolic acid copolymer
Brain

Keywords

  • Blood-brain barrier
  • Cancer chemotherapy
  • Coating
  • MDCK
  • Nanoparticles

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer. / Xie, Jingwei; Lei, Chenlu; Hu, Yong; Gay, Gary Kaizhong; Jamali, Nazrul Hadi Bin; Wang, Chi Hwa.

In: Current Pharmaceutical Design, Vol. 16, No. 21, 20.08.2010, p. 2331-2340.

Research output: Contribution to journalArticle

Xie, Jingwei ; Lei, Chenlu ; Hu, Yong ; Gay, Gary Kaizhong ; Jamali, Nazrul Hadi Bin ; Wang, Chi Hwa. / Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer. In: Current Pharmaceutical Design. 2010 ; Vol. 16, No. 21. pp. 2331-2340.
@article{30791c48728d434f8390df7a22bf7d39,
title = "Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer",
abstract = "Paclitaxel appears to be a potential substrate of the multidrug resistance protein p-glycoprotein, thus preventing itself from entry into the brain and penetrating blood-brain barrier poorly. In this study, the main objective was to design paclitaxel formulation using PLGA-based nanoparticles with different additives and surface coatings to facilitate the paclitaxel transport through MDCK cell monolayer. PLGA-based nanoparticles of around 200 nm without and with additives and surface coatings were developed by direct dialysis. The transendothelial electrical resistance (TEER) variation of MDCK cell monolayer on the cell inserts imposed by paclitaxel-loaded nanoparticles with and without additives was investigated. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) (MTT) assay was used to quantify the cell viability of C6 glioma cells after administration of formulations on the topical side. Investigations showed that particles with additives were able to enhance cellular uptake more than surface-coated particles. TEER values dropped upon the introduction of paclitaxel-loaded PLGA nanoparticles to the cell inserts. After incubation for 24 h, the cell viability of C6 glioma cells in the wells treated with nanoparticles was lower than that of the control wells without particles. Taken together, PLGA nanoparticles with vitamin E TPGS and polysorbate 80 as additives were successfully obtained as paclitaxel formulations, demonstrating great potential for the delivery of paclitaxel through MDCK cell monolayer in vitro.",
keywords = "Blood-brain barrier, Cancer chemotherapy, Coating, MDCK, Nanoparticles",
author = "Jingwei Xie and Chenlu Lei and Yong Hu and Gay, {Gary Kaizhong} and Jamali, {Nazrul Hadi Bin} and Wang, {Chi Hwa}",
year = "2010",
month = "8",
day = "20",
doi = "10.2174/138161210791920432",
language = "English (US)",
volume = "16",
pages = "2331--2340",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "21",

}

TY - JOUR

T1 - Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer

AU - Xie, Jingwei

AU - Lei, Chenlu

AU - Hu, Yong

AU - Gay, Gary Kaizhong

AU - Jamali, Nazrul Hadi Bin

AU - Wang, Chi Hwa

PY - 2010/8/20

Y1 - 2010/8/20

N2 - Paclitaxel appears to be a potential substrate of the multidrug resistance protein p-glycoprotein, thus preventing itself from entry into the brain and penetrating blood-brain barrier poorly. In this study, the main objective was to design paclitaxel formulation using PLGA-based nanoparticles with different additives and surface coatings to facilitate the paclitaxel transport through MDCK cell monolayer. PLGA-based nanoparticles of around 200 nm without and with additives and surface coatings were developed by direct dialysis. The transendothelial electrical resistance (TEER) variation of MDCK cell monolayer on the cell inserts imposed by paclitaxel-loaded nanoparticles with and without additives was investigated. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) (MTT) assay was used to quantify the cell viability of C6 glioma cells after administration of formulations on the topical side. Investigations showed that particles with additives were able to enhance cellular uptake more than surface-coated particles. TEER values dropped upon the introduction of paclitaxel-loaded PLGA nanoparticles to the cell inserts. After incubation for 24 h, the cell viability of C6 glioma cells in the wells treated with nanoparticles was lower than that of the control wells without particles. Taken together, PLGA nanoparticles with vitamin E TPGS and polysorbate 80 as additives were successfully obtained as paclitaxel formulations, demonstrating great potential for the delivery of paclitaxel through MDCK cell monolayer in vitro.

AB - Paclitaxel appears to be a potential substrate of the multidrug resistance protein p-glycoprotein, thus preventing itself from entry into the brain and penetrating blood-brain barrier poorly. In this study, the main objective was to design paclitaxel formulation using PLGA-based nanoparticles with different additives and surface coatings to facilitate the paclitaxel transport through MDCK cell monolayer. PLGA-based nanoparticles of around 200 nm without and with additives and surface coatings were developed by direct dialysis. The transendothelial electrical resistance (TEER) variation of MDCK cell monolayer on the cell inserts imposed by paclitaxel-loaded nanoparticles with and without additives was investigated. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) (MTT) assay was used to quantify the cell viability of C6 glioma cells after administration of formulations on the topical side. Investigations showed that particles with additives were able to enhance cellular uptake more than surface-coated particles. TEER values dropped upon the introduction of paclitaxel-loaded PLGA nanoparticles to the cell inserts. After incubation for 24 h, the cell viability of C6 glioma cells in the wells treated with nanoparticles was lower than that of the control wells without particles. Taken together, PLGA nanoparticles with vitamin E TPGS and polysorbate 80 as additives were successfully obtained as paclitaxel formulations, demonstrating great potential for the delivery of paclitaxel through MDCK cell monolayer in vitro.

KW - Blood-brain barrier

KW - Cancer chemotherapy

KW - Coating

KW - MDCK

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=77955629588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955629588&partnerID=8YFLogxK

U2 - 10.2174/138161210791920432

DO - 10.2174/138161210791920432

M3 - Article

C2 - 20618154

AN - SCOPUS:77955629588

VL - 16

SP - 2331

EP - 2340

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 21

ER -